Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers find gene variants that cause stent thrombosis in people with coronary artery disease

26.10.2011
In a first-of-its-kind study, researchers from Mount Sinai School of Medicine have discovered several gene variants contributing to early stent thrombosis (ST), a devastating and often deadly complication after coronary stent implantation in people with coronary artery disease.

The team found that three of these variants were associated with impaired sensitivity to the common blood thinner clopidogrel, and a fourth that affects a blood platelet receptor involved in platelet aggregation and clot formation. Analyzing these gene variants will help researchers identify patients at risk for early stent thrombosis and take measures to prevent it.

The data also provide a clinical and genomic score that indicates the best predictive accuracy for stent thrombosis risk. The findings are published in the Oct. 26 issue of the Journal of the American Medical Association.

Through a partnership with the Institut de Cardiologie at Pitié-Salpêtrière University Hospital in Paris, France, the research team evaluated the DNA of 123 patients who had undergone stent implantation and developed early ST while treated with dual antiplatelet therapy, which is a combination of aspirin and clopidogrel. The patient information was shared as part of ONline ASSIstance for Stent Thrombosis (ONASSIST), a nationwide web registry of patients in France.

Looking at 23 genetic variants previously associated with clopidogrel metabolism, platelet receptor function, and the control of blood clotting, they found four that were predictive risk factors of early ST. They also found that a low dose of clopidogrel in combination with a proton pump inhibitor, which is a drug to treat acid reflux, also increased the risk of early ST.

"Our research indicates that early stent thrombosis is strongly related to ineffectiveness of clopidogrel in certain patients," said Jean-Sebastien Hulot, MD PhD, Associate Professor of Medicine in the Division of Cardiology and Director Pharmacogenomics and Personalized Therapeutics at the Cardiovascular Research Center at Mount Sinai School of Medicine. "Now that we have a clearer understanding of the mechanism behind the development of stent thrombosis, we can take preventive measures to protect our patients from this deadly complication."

The research team compared the genetic code of people registered in the ONASSIST program with 246 coronary patients without early ST. They evaluated alleles, which are types of genetic variation that arise from mutations, of 23 genes. They found that CYP2C19*2 allele, which is commonly associated with loss of enzyme function, was highly prevalent in people presenting with early ST, as was the allele ABCB1 3435T, and both were infrequent in the control group. Two other alleles, CYP2C19*17 and ITGB3, were prevalent in the healthy control group but not in the early ST group indicating a protective effect. The scientists developed a genetic score where the more of these mutations that the patient had, the higher their risk for developing early ST. This risk was independent of clinical risk factors, including the use of proton pump inhibitors, acuteness of PCI, complexity of cardiac lesions, left ventricular heart function, and a high dose of clopidogrel. Only two of these risk factors– clopidogrel dose and proton pump inhibitor use – are modifiable in reducing risk for early ST. Eventually, the best prediction was achieved using the combination of both clinical and genetic factors. The authors conclude that this "clinico-genomic" approach could be useful prior to stent implantation to identify the patients with high-ST risk.

"We found that, independent of other clinical risk factors, these genetic factors play a critical role in the development of early ST," said Dr. Hulot. "Altogether, our data will help clinicians understand the factors contributing to early ST, and allow them to reduce the outcome risk to these patients. Understanding the genetic factors provides researchers with new drug targets for future study to reduce the genetic risk as well."

Mount Sinai's Cardiovascular Research Center plans to continue the partnership with the Institut de Cardiologie at Pitié-Salpêtrière University Hospital in Paris to develop an international cardiogenomic laboratory to better understand genetic risk factors associated with heart disease and treatments for heart disease to improve and better target clinical care for patients.

PCI is a minimally invasive technique used to treat patients with diseased coronary arteries caused by a buildup of plaque and cholesterol. During the procedure, a catheter is threaded through the body, typically from an artery in the groin to a blocked or occluded vessel in the heart. The occlusion is removed and a stent is often inserted to maintain flow within the blood vessel. Up to four percent of patients undergoing PCI experience early ST, which is deadly in 40 percent of those patients.

Mount Sinai Press Office | EurekAlert!
Further information:
http://www.mssm.edu

More articles from Health and Medicine:

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

nachricht Periodic ventilation keeps more pollen out than tilted-open windows
29.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>